1. A method of detecting grind burn on an object being ground, comprising:
removing material from an object during a grinding operation;
collecting the material from the object with an element during the grinding operation;
inspecting the collected material for an indication of grind burn; and
inferring grind burn when the indication is a discoloration or change in thickness of the collected material.
2. The method of claim 1, wherein the indication is substantially dark gray, blue, or black.
3. The method of claim 1, wherein the element comprises filter paper or a magnet.
4. The method of claim 3, further comprising placing filter paper near the object.
5. The method of claim 3, wherein the filter paper is placed substantially beneath the object.
6. The method of claim 3, further comprising aligning the filter paper with the object.
7. The method of claim 6, further comprising correlating the location of the collected material on the filter paper with the location on the object from which the material is removed.
8. The method of claim 1, further comprising using an instrument to inspect the collected material.
9. The method of claim 8, wherein the instrument is a camera or microscope.
10. The method of claim 9, further comprising magnifying the collected material to inspect for the indication.
11. The method of claim 1, further comprising comparing the thickness of the collected material with a threshold thickness.
12. The method of claim 1, further comprising generating a warning signal when grind burn is inferred.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A sustained release composition comprising
a carrier substrate and
a protein drug incorporated into the carrier substrate,
said carrier substrate comprising
(a) a hyaluronic acid or its salt, having a molecular weight of at least 3,000,000 Da,
(b) a polyalkyl oxide, and
(c) an amino acid wherein the amino acid is selected from the group consisting of aspartic acid, histidine, isoleucine, leucine, methionine, valine and a combination or at least two of the foregoing amino acids,
wherein a ratio of a molecular weight (Da) of the protein drug to a molecular weight (Da) of the polyalkyl oxide is about 1:0.5-1:1.8
2. The composition according to claim 1, wherein a total amount of the hyaluronic acid or its salt, the polyalkyl oxide and the amino acid is about 50-99.95% by weight based on dry weight of the composition.
3. The composition according to claim 2, wherein the total amount of the hyaluronic acid or its salt, the polyalkyl oxide and the amino acid is about 70-99.95% by weight based on dry weight of the composition.
4. The composition according to claim 1, wherein the polyalkyl oxide is a polyethylene glycol, a polypropylene glycol, a copolymer thereof, or a mixture thereof.
5. The composition according to claim 4, wherein the polyalkyl oxide is a polyethylene glycol.
6. The composition according to claim 5, wherein the polyalkyl oxide has a molecular weight of at least 1,000 Da.
7. The composition according to claim 1, wherein the protein drug is an interferon, erythropoietin, or a follicle stimulating hormone.
8. The composition according to claim 1, which further comprises a stabilizer.
9. The composition according to claim 1, wherein the ratio of the molecular weight (Da) of the protein drug to the molecular weight (Da) of the polyalkyl oxide is about 1:1.
10. The composition according to claim 1, which is formulated into microparticles, pellets, rods, filaments, cylinders, or films.
11. A pharmaceutical formulation for injection, which comprises the composition according to claim 1 dispersed in an injection medium.
12. The pharmaceutical formulation according to claim 11, wherein the injection medium is selected from the group consisting of distilled water; a buffer; corn oil, sesame oil, cotton seed oil, soybean oil, peanut oil, mono-glyceride, di-glyceride, tri-glyceride, mineral oil, squalene, and mixtures thereof.
13. An aerosol formulation comprising the composition according to claim 1.
14. A sustained release composition comprising
a carrier substrate and
a protein drug incorporated into the carrier substrate,
said carrier substrate being comprising
(a) a hyaluronic acid or its salt having molecular weight of at least 3,000,000 Da,
(b) a polyethylene glycol, and
(c) an amino acid selected from the group consisting of aspartic acid, histidine, isoleucine, leucine, methionine, valine, and a combination of at least two of the foregoing amino acids,
wherein a ratio of a molecular weight (Da) of the protein drug to a molecular weight (Da) of the polyethylene glycol is about 1:0.8-1:1.8 and the molecular weight of the polyethylene glycol is at least 1,000 Da.
15. The composition according to claim 1, wherein the protein drug is contained in an amount of 0.05-5% by weight based on a dry weight of the composition.
16. The composition according to claim 1, wherein the hyaluronic acid or its salts is contained in an amount of 20-50% by weight based on a dry weight of the composition.
17. The composition according to claim 1, wherein the polyalkyl oxide is contained in an amount of 5-60% by weight based on a dry weight of the composition.
18. The composition according to claim 1, wherein the amino acid is contained in an amount of 10-80% by weight based on a dry weight of the composition.
19. The composition according to claim 1, wherein the amino acid is selected from the group consisting of aspartic acid, histidine, isoleucine, leucine, methionine, and a combination of at least two of the foregoing amino acids.